Return to homepagePandemic Pact

COVID-19 Impact on Medications for Opioid Use Disorder Participants, Treatment, and Outcomes: Disparate COVID-19 Vulnerability and Impact of Unique Natural Experiments

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $100,000

  • Funder

    FORE

  • Principal Investigator

    PhD. Stephen Crystal

  • Research Location

    United States of America

  • Lead Research Institution

    Rutgers Institute for Health, Health Care Policy and Aging Research

  • Research Priority Alignment

    N/A

  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    Indirect health impacts

  • Special Interest Tags

    Digital Health

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

During the pandemic, policymakers in New Jersey and other states have relaxed regulations for prescribing medications for opioid use disorder for Medicaid beneficiaries. This project would analyze Medicaid data and interviews with opioid treatment providers to see how the policy changes and resulting treatment adaptations, including increased telemedicine usage, longer methadone take-home doses, reduced drug screening, and reduced in-person counseling, have affected access to care and treatment outcomes.